Table 1. Clinicopathological correlation of miR-9 expression in ESCC.
| Feature | miR-9 expression level | |||
|---|---|---|---|---|
| All | Normal | Upregulated | P | |
| Age | 0.069 | |||
| ≥60 years | 139 | 98(70.5) | 41(29.5) | |
| >60 years | 104 | 63(60.6) | 41(39.4) | |
| Differentiation | 0.093 | |||
| Well | 60 | 33(55.0) | 27(45.0) | |
| Moderate | 156 | 108(69.2) | 48(30.8) | |
| Poor | 27 | 20(74.1) | 7(25.9) | |
| Tumer invasion | 0.705 | |||
| T1 | 18 | 12(66.7) | 6(33.3) | |
| T2 | 18 | 10(55.6) | 8(44.4) | |
| T3 | 45 | 32(71.1) | 13(28.9) | |
| T4 | 162 | 107(66.0) | 55(34.0) | |
| Lymph node metastasis | 0.007* | |||
| N0 | 138 | 101(73.2) | 37(26.8) | |
| N1 | 105 | 60(57.1) | 45(42.9) | |
| Clinical stage | 0.022* | |||
| Stage I-II | 161 | 115(71.4) | 46(28.6) | |
| Stage III-IV | 82 | 46(56.1) | 36(43.9) | |
*
Significant difference